Efficacy of Kangliuwan for Recurrent Grade IV Glioma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Recurrent grade IV glioma patients and conventional treatment is invalid.
The patient signed "informed consent" voluntarily;
The age of patient is between 18 and 80 years;
KPS score ≥40 ; The patient has normal liver and kidney function Normal heart function Better follow-up and compliance;
The patient did not sign "informed consent" or signed unvoluntarily.
Human immunodeficiency virus (HIV) positive
Hepatitis C or hepatitis B infective
Pregnancy or breast-feeding women
Patients did not agree to use effective contraception during treatment and the following 3 months.
Patients also participated in other clinical studies.
The subjects researchers believe are not suitable for participation or completion of the study.